Luis Carlos Clavijo-Moreno

Luis Carlos Clavijo-Moreno

Auto-generated profile, based on publicly available information

Luis Carlos Clavijo-Moreno

Fundación Santa Fe de Bogotá - Departamento de Otorrinolaringología - Bogotá D.C. - Colombia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Boletín de Malariología y Salud Ambiental
Verified
Journal Article
Closed access
PDF file
YFYesid Fabian Mantilla Flórez
Yesid Fabian Mantilla Flórez
ETEduardo Tuta-Quintero
Eduardo Tuta-Quintero
ABAbraham Jose Brito-Rodriguez
Abraham Jose Brito-Rodriguez
LCLuis Carlos Clavijo-Moreno
Luis Carlos Clavijo-Moreno
La candidiasis es una enfermedad micótica debida a levaduras pertenecientes al género Candida. Dentro del gran conjunto de microorganismos que colonizan al ser humano, Candida albicans es el agente etiológico más comúnmente detectado ya que habita como comensal en las superficies mucosas y la piel. C. albicans participa en procesos de fermentación de azúcares y asimilación de nutrientes, pero, en algunas ocasiones se relaciona con procesos patológicos. En los últimos años los avances tecnológicos y médicos; así como el aumento en la incidencia de infecciones por el virus de la inmunodeficiencia humana, el auge creciente de la terapia inmunomoduladora y el uso de antibióticos de amplio espectro durante largos períodos de tiempo se han convertido en los factores de riesgo más importantes para la creciente incidencia de infecciones por microorganismos del género Candida. Debido a esto, resulta imperativo el conocimiento de esta enfermedad y sus formas clínicas más importantes, así como el abordaje diagnóstico y el tratamiento actual; información que recolectamos en este documento para brindar una visión general sobre esta patología.

12 February 2026 in Revista de la Facultad de Medicina
Verified
Journal Article
Open access
PDF file
CVCarlos Arides Vargas-Rueda
Carlos Arides Vargas-Rueda
JSJohan Andrés Salcedo-Cumplido
Johan Andrés Salcedo-Cumplido
AAAngela Aguirre-Rodriguez
Angela Aguirre-Rodriguez
LCLuis Carlos Clavijo-Moreno
Luis Carlos Clavijo-Moreno
Introduction: Laryngeal tuberculosis (LTB) accounts for less than 1% of all tuberculosis cases. Its diagnosis is complex due to its non-specific clinical manifestations in the larynx. Case presentation: A 78-year-old man presented to the emergency room of a hospital in Bogotá D.C. (Colombia) with exertional dyspnea, dry cough, dysphonia, odynophagia, and dysphagia over the last 3 months, with worsening of respiratory symptoms in the last 24 hours. Admission laboratory tests showed an elevated D-dimer level; therefore, due to suspected pulmonary thromboembolism, a contrast-enhanced CT chest angiography was performed. No signs of thromboembolism were observed, but centrilobular lung micronodules, a tree-in-bud pattern, and changes related to previous pulmonary fibrosis were observed. Due to the risk of aspiration, a nasopharyngoscopy was performed, finding leukoplakia on the right ventricular fold and the right vocal fold. Based on these findings, a biopsy of the lesions, acid-fast bacilli (AFB) staining, and a PCR test for Mycobacterium tuberculosis were requested, all of which were positive. Antituberculosis therapy (RHZE 150/75/400/275 mg) was initiated 5 days after diagnosis once his condition was stabilized; the biopsy was postponed for the same reason. Given the favorable response, he was discharged 4 days after starting treatment. A follow-up nasolaryngoscopy at 30 days showed a significant reduction in the pseudotumoral lesions on the ventricular fold and complete resolution on the vocal fold. At the 3-month follow-up, respiratory symptoms had improved considerably. Conclusion: Although it is a very rare condition, LTB should be considered as a differential diagnosis in patients with non-specific symptoms (such as dysphonia, dysphagia, and odynophagia) and laryngeal lesions, even in countries without a high TB burden like Colombia. Timely initiation of anti-tuberculosis therapy is essential to prevent serious complications, given the excellent and rapid response to this treatment.